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Duloxetine metabolism in the presence of cytochrome P450 inhibitors
Astyia Golden
Dr. Myoung E. Lee, Dr. Emily F. Ruff
Cytochrome P450 (CYP) enzymes are important for drug metabolism. They chemically
modify drugs to make them more soluble, which allows the drugs to be excreted from the body.
Of the 30 CYP enzymes, 6 (CYP1A2, 2C9, 2C19, 2D6, 2E1, 3A4/5) are of clinical interest because
these enzymes are the key players in drug metabolism. Differences in genetics lead to
individuals of the same species expressing different CYP enzymes. The different combination of
CYP enzymes may affect the rate of drug metabolism or produce metabolites that may cause
adverse side effects. Predicting drug metabolites and drug-drug interactions is important when
designing and prescribing new drugs because other drugs can act as CYP activators or inhibitors.
Duloxetine is an antidepressant mainly metabolized by CYP1A2 and CYP2D6 isotypes. In this
experiment, Duloxetine was metabolized using rat microsomes, housing a variety of CYP
isotypes. Efficiency of metabolism in the presence and absence of inhibitors was measured
using HPLC-MS.

Introduction:
For most drugs to be excreted from the body, they must first be inactivated and made
more soluble. Cytochrome P450 (abbreviated as “CYP”) isozymes are heme-containing
membrane proteins that chemically modify drugs for metabolism, most commonly via
oxidation.1 These proteins are found in the smooth endoplasmic reticulum of cells located in
the liver, intestines, lungs, kidneys, plasma, and skin. The main site of drug metabolism in the
human body is the liver, therefore, P450 enzyme concentration and activity is highest in hepatic
cells.3
CYP enzymes have been categorized using a common nomenclature system that
includes the family name, subfamily, and the individual gene that encodes the enzyme. There
are more than 30 P450 enzymes that have been identified in human cells and belong to families
1-4. An estimated 90% of drug metabolism has been attributed to six P450 enzymes including
CYP1A2, 2C9, 2C19, 2D6, 2E1, 3A4/5 making these enzymes of greatest clinical interest.2
Drug metabolism varies from one person to the next. This is due to the wide variety of
P450 enzymes expressed in individuals and their effectiveness. Common variations, or
polymorphisms, in the genes encoding the CYP enzymes can affect their function, either
increasing or decreasing their rate of metabolism.3 These differences in enzyme presence and
effectiveness can cause different rates of drug metabolism from one individual to the next and
can lead to adverse side effects. Some drugs can act as either CYP activators or inhibitors. CYP
activators increase the rate of drug metabolism causing the drug to be excreted at a faster rate.
This may cause the effects of the drug to be decreased or lost. Most CYP activators function by
increasing expression of CYP enzymes. CYP inhibitors decrease the rate of drug metabolism.
This can lead to a toxic buildup of the drug.4 Being able to predict and manipulate drug
metabolites is useful when designing new drugs to decrease side effects, and can help predict
drug-drug interactions when an individual is prescribed multiple drugs that share the same
pathway.
In this project, I analyzed the drug metabolites of a soluble antidepressant, duloxetine.
Duloxetine is most commonly metabolized by CYP1A2 and CYP2D6, like many other
antidepressants. Previous studies have shown a decrease in the production of duloxetine
metabolites in the presence of both CYP1A2 and CYP2D6 isozyme specific CYP inhibitors.5
Therefore, these specific CYP enzymes are important for metabolism of duloxetine.
Metabolites were produced by incubating duloxetine with rat microsomes containing
CYP enzymes of various isotypes. Metabolite production was monitored using HPLC-MS. HPLCMS is a useful tool to separate and identify components in a mixture, the machine is equipped
with a C18 column that separates the components based on polarity. The efficiency of drug
metabolism was manipulated by adding a general cytochrome P450 inhibitor, SKF-525A. SKF525A is a broad spectrum CYP inhibitor that inhibits CYP activity of all isotypes.6 Broad inhibition
is expected to show an overall decrease in the percentage of metabolites produced and an
increased concentration of duloxetine remaining in the sample.
Experimental Methods:
Duloxetine can be metabolized in vitro when incubated with rat microsomes housing a
variety of CYP enzymes, with or without an NADPH-generating system. To observe the effects of

CYP inhibition on metabolite production a broad spectrum CYP inhibitor, SKF-525A, was added
to the incubation mixture.
Rat microsomes, SKF-525A, NADP, G6P, and G6P dehydrogenase were purchased from
Sigma-Aldrich and Duloxetine was kindly provided by Dr. Myoung Lee. A 50 mM phosphate
buffer (pH 7.4) was used to make a stock solution of Duloxetine with a concentration of 1.6 mM
and a stock solution of SKF-525A with a concentration of 1.85 mM. Using these stocks,
incubation mixtures were prepared by adding 65 µl of either drug or drug + inhibitor, combined
with 25 µl of rat microsomes, and 35 µl of additional buffer. Experimental controls included a
sample containing only duloxetine and buffer and a sample with only SKF-525A and buffer.
Tubes were incubated for 2 hours. After incubation, 250 µl of methanol was added to stop the
reaction. Tubes were centrifuged at top speed for 20 minutes and the supernatant from each
tube was extracted and placed in a new tube. The tubes were stored in the freezer until they
were run on the HPLC-MS. HPLC separates the components of a mixture and uses absorbance
to identify them. The absorbance was measured at 214 nm and 290 nm. 290 nm is a reference
wavelength to measure absorbance of the sample overall. 214 nm was chosen because the
absorbance of duloxetine is maximized at 214 nm. Components of the mixture can be ionized
and separated based on their mass to charge ratio by the mass spectrometer. A gradient of 5
mM ammonium acetate in water and 5 mM ammonium acetate in acetonitrile and water (95:5)
was used. The gradient started at 95% ammonium acetate in water and decreased to 5%. The
run time was 35 minutes for each sample. The sample contained 50 µl of the incubation
mixture diluted with 1 ml of ammonium acetate in water. The sample was run through the
HPLC connected with the mass spectrometer and the type and percentage of each metabolite
was determined using SIM and TIC filtered data.
Results:
SmartCYP, a freely available online algorithm, was used to predict the metabolites of
duloxetine.

Figure 1: According to this algorithm the most common metabolites of duloxetine by CYP 2D6
should be hydroxylated and N-demethylated products. We are not able to distinguish between
hydroxylated products using the HPLC-MS.

Figure 2: According to this algorithm the most common metabolites of duloxetine by CYP 3A4
should also be hydroxylated and N-demethylated products, but hydroxylation may occur at the
nitrogen or amino carbon, rather than an aromatic carbon. This is predicted due to the different
size of the CYP 3A4 and 2D6 active sites.

Figure 3: Duloxetine is at the center with its metabolites including N-desmethyl duloxetine and
4-hydroxy duloxetine on either side. Duloxetine with a methyl group removed creates Ndesmethyl duloxetine while addition of a hydroxyl group creates 4-hydroxy duloxetine. The
molecular weights listed are after polarization of the molecule.
Trial

Percent of Ndesmethyl duloxetine

Percent of
unmetabolized
duloxetine
0%

Percent of 4hydroxy
duloxetine
28.5%

Duloxetine without
71.5%
inhibitor
Duloxetine with
65.1%
10.4%
24.5%
inhibitor
Table 1: Percentage of unmetabolized duloxetine and of each metabolite produced was
determined using the total ion chromatogram from the mass spectrometer.

Figure 4: Chromatogram of duloxetine after metabolism by CYP enzymes.

Figure 5: Chromatogram of duloxetine after metabolism by CYP enzymes in the presence of
SKF-525A, a general CYP inhibitor.

Discussion:
The peaks in the chromatogram were more spread out than expected, and the intensity
of the peaks was very low. This may be due to duloxetine and its metabolites sticking to the C18
column, or to product loss at some step in the procedure. Future experiments would aim to get
single, more pronounced peaks for each metabolite in the HPLC and mass spectrum data. This
could possibly be achieved by modifying the gradient parameters on the HPLC, using different
solvents for the gradient, or injecting the sample directly into the mass spectrometer instead of
using the HPLC-MS combined. Injecting the sample directly into the mass spectrometer could
produce more pronounced peaks by eliminating sample loss that may occur when passing
through the C18 column of the HPLC.
By analyzing the total ion chromatogram, we found that duloxetine without the inhibitor
showed 100% metabolism. Metabolism was reduced by 10% in the presence of CYP inhibitor,
SKF-525A. In both cases metabolism was high, most likely because there was a high
concentration of rat microsomes added to both samples. A study, completed by previous
research student, Dani Schmaus, diluted the microsomes with phosphate buffer. For this
experiment, 25 µl of undiluted rat microsomes were added to the incubation mixture,
producing very high rates of metabolism. Another manipulation to the protocol was the
removal of the NADPH-generating system. Previous research, by Dani Schmaus, also showed
that the NADPH-generating system was not necessary to metabolize duloxetine. Removal of
this system reduced the cost of the experiment, eliminated steps to create the NADPHgenerating system from the procedure, as well as cleaned up the sample overall by decreasing
impurities in the sample. An increase in CYP inhibition and metabolite production could be seen
in future experiments if the concentration of duloxetine was decreased, concentration of SKF525A was increased, rat microsome concentration was decreased, or isotype specific CYP
inhibitors were used.
There is still a lot that could be done to improve or expand on this project. Possible
future experiments include using isotype specific CYP inhibitors to see increased effects of
inhibition on Duloxetine metabolism. Duloxetine is mainly metabolized by CYP enzymes 1A2
and 2D6. Therefore, it would be expected that using isotype specific CYP 1A2 and 2D6 inhibitors
would show greater inhibition than a general CYP inhibitor like SKF-525A. This procedure can
also be manipulated to predict and analyze metabolism of drugs other than antidepressants.

Predicting drug metabolism is a powerful and useful tool in the pharmaceutical and medical
industry to ensure the drugs that are being designed and prescribed to patients are safe.
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